Comparison of bypassing agents in patients on emicizumab using global hemostasis assays
Sign Up to like & getrecommendations! Published in 2020 at "Haemophilia"
DOI: 10.1111/hae.14213
Abstract: Emicizumab is a humanized bispecific monoclonal antibody licensed for patients with severe haemophilia A with and without inhibitors. Management of breakthrough bleeding in patients with inhibitors on emicizumab involves episodic treatment with bypassing agents (BPA),… read more here.
Keywords: patients emicizumab; comparison bypassing; agents patients; bypassing agents ... See more keywords